Literature DB >> 10102434

Subacute measles encephalitis in a young man immunosuppressed for ankylosing spondylitis.

P Gazzola1, L Cocito, E Capello, L Roccatagliata, M Canepa, G L Mancardi.   

Abstract

Subacute measles encephalitis occurred 1 month after measles onset in a 26-year-old HIV-negative man undergoing immunosuppressive treatment for ankylosing spondylitis. He had seizures, a decline in mental status, and progressive impairment of consciousness, with a fatal outcome. Despite severely deficient cellular immunity, the elevated antimeasles antibody titers and CSF findings indicated that humoral immunity was not impaired. Histologic, electron microscopic, and immunocytochemical studies revealed the typical intranuclear inclusions of paramyxovirus nucleocapsids, and measles virus antigen in neurons and oligodendrocytes.

Entities:  

Mesh:

Year:  1999        PMID: 10102434     DOI: 10.1212/wnl.52.5.1074

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  4 in total

1.  Canine distemper virus uses both the anterograde and the hematogenous pathway for neuroinvasion.

Authors:  Penny A Rudd; Roberto Cattaneo; Veronika von Messling
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

2.  Productive measles virus brain infection and apoptosis in CD46 transgenic mice.

Authors:  A Evlashev; E Moyse; H Valentin; O Azocar; M C Trescol-Biémont; J C Marie; C Rabourdin-Combe; B Horvat
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

3.  High pathogenicity of wild-type measles virus infection in CD150 (SLAM) transgenic mice.

Authors:  Caroline I Sellin; Nathalie Davoust; Vanessa Guillaume; Dominique Baas; Marie-Françoise Belin; Robin Buckland; T Fabian Wild; Branka Horvat
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

4.  A 16-year old male with cortical blindness and focal motor seizures.

Authors:  S M Katrak; A Mahadevan; Arun B Taly; S Sinha; S K Shankar
Journal:  Ann Indian Acad Neurol       Date:  2010-07       Impact factor: 1.383

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.